212 related articles for article (PubMed ID: 18313756)
1. Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.
Hwang HY; Duvall MR; Tomlinson S; Boackle RJ
Mol Immunol; 2008 May; 45(9):2570-80. PubMed ID: 18313756
[TBL] [Abstract][Full Text] [Related]
2. Specific inhibition of the classical complement pathway with an engineered single-chain Fv to C1q globular heads decreases complement activation by apoptotic cells.
Duvall MR; Hwang HY; Boackle RJ
Immunobiology; 2010 May; 215(5):395-405. PubMed ID: 19586684
[TBL] [Abstract][Full Text] [Related]
3. High molecular weight non-immunoglobulin salivary agglutinins (NIA) bind C1Q globular heads and have the potential to activate the first complement component.
Boackle RJ; Connor MH; Vesely J
Mol Immunol; 1993 Feb; 30(3):309-19. PubMed ID: 8433709
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of a recombinant form of the C-terminal, globular head region of the B-chain of human serum complement protein, C1q.
Kishore U; Leigh LE; Eggleton P; Strong P; Perdikoulis MV; Willis AC; Reid KB
Biochem J; 1998 Jul; 333 ( Pt 1)(Pt 1):27-32. PubMed ID: 9639558
[TBL] [Abstract][Full Text] [Related]
5. A recombinant homotrimer, composed of the alpha helical neck region of human surfactant protein D and C1q B chain globular domain, is an inhibitor of the classical complement pathway.
Kishore U; Strong P; Perdikoulis MV; Reid KB
J Immunol; 2001 Jan; 166(1):559-65. PubMed ID: 11123337
[TBL] [Abstract][Full Text] [Related]
6. Complement activation by IgG containing immune complexes regulates the interaction of C1q with its ligands.
Hester CG; Frank MM
Mol Immunol; 2019 Dec; 116():117-130. PubMed ID: 31634815
[TBL] [Abstract][Full Text] [Related]
7. Localization of ligand-binding sites on human C1q globular head region using recombinant globular head fragments and single-chain antibodies.
Kojouharova MS; Tsacheva IG; Tchorbadjieva MI; Reid KB; Kishore U
Biochim Biophys Acta; 2003 Nov; 1652(1):64-74. PubMed ID: 14580997
[TBL] [Abstract][Full Text] [Related]
8. Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System.
Laursen NS; Pedersen DV; Gytz H; Zarantonello A; Bernth Jensen JM; Hansen AG; Thiel S; Andersen GR
Front Immunol; 2020; 11():1504. PubMed ID: 32849513
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q.
Nauta AJ; Bottazzi B; Mantovani A; Salvatori G; Kishore U; Schwaeble WJ; Gingras AR; Tzima S; Vivanco F; Egido J; Tijsma O; Hack EC; Daha MR; Roos A
Eur J Immunol; 2003 Feb; 33(2):465-73. PubMed ID: 12645945
[TBL] [Abstract][Full Text] [Related]
10. Rat polymeric IgA binds C1q, but does not activate C1.
Hiemstra PS; Rits M; Gorter A; Stuurman ME; Hoekzema R; Bazin H; Vaerman JP; van Es LA; Daha MR
Mol Immunol; 1990 Sep; 27(9):867-74. PubMed ID: 2215479
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the envelope glycoprotein of human immunodeficiency virus with C1q and fibronectin under conditions present in human saliva.
Su H; Boackle RJ
Mol Immunol; 1991 Aug; 28(8):811-7. PubMed ID: 1875953
[TBL] [Abstract][Full Text] [Related]
12. Evidence that C1q binds specifically to CH2-like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation.
Kovacs H; Campbell ID; Strong P; Johnson S; Ward FJ; Reid KB; Eggleton P
Biochemistry; 1998 Dec; 37(51):17865-74. PubMed ID: 9922153
[TBL] [Abstract][Full Text] [Related]
13. The distortive mechanism for the activation of complement component C1 supported by studies with a monoclonal antibody against the "arms" of C1q.
Hoekzema R; Martens M; Brouwer MC; Hack CE
Mol Immunol; 1988 May; 25(5):485-94. PubMed ID: 3261834
[TBL] [Abstract][Full Text] [Related]
14. C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities.
Chen CH; Lam CF; Boackle RJ
Immunology; 1998 Dec; 95(4):648-54. PubMed ID: 9893058
[TBL] [Abstract][Full Text] [Related]
15. New insights into the molecular mechanisms of classical complement activation.
Kojouharova M; Reid K; Gadjeva M
Mol Immunol; 2010 Aug; 47(13):2154-60. PubMed ID: 20542571
[TBL] [Abstract][Full Text] [Related]
16. Specific inhibition of the classical complement pathway by C1q-binding peptides.
Roos A; Nauta AJ; Broers D; Faber-Krol MC; Trouw LA; Drijfhout JW; Daha MR
J Immunol; 2001 Dec; 167(12):7052-9. PubMed ID: 11739526
[TBL] [Abstract][Full Text] [Related]
17. A newly discovered function for C1 inhibitor, removal of the entire C1qr2s2 complex from immobilized human IgG subclasses.
Chen CH; Boackle RJ
Clin Immunol Immunopathol; 1998 Apr; 87(1):68-74. PubMed ID: 9576012
[TBL] [Abstract][Full Text] [Related]
18. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.
Thommesen JE; Michaelsen TE; Løset GÅ; Sandlie I; Brekke OH
Mol Immunol; 2000 Nov; 37(16):995-1004. PubMed ID: 11395138
[TBL] [Abstract][Full Text] [Related]
19. Binding of complement component C1q to anti-beta2 glycoprotein I antibodies from patients with antiphospholipid syndrome.
Odorczuk M; Keil LB; DeBari VA
Inflamm Res; 1999 Oct; 48(10):524-6. PubMed ID: 10563468
[TBL] [Abstract][Full Text] [Related]
20. Classical complement pathway component C1q: purification of human C1q, isolation of C1q collagen-like and globular head fragments and production of recombinant C1q-derivatives. Functional characterization.
Kojouharova M
Methods Mol Biol; 2014; 1100():25-42. PubMed ID: 24218248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
